Skip to Main Content

  1. Pharmacology

    1. Magnesium is the fourth most common cation in the body and the second most abundant intracellular cation after potassium. Magnesium plays an essential role as an enzymatic cofactor in a number of biochemical pathways, including energy production from adenosine triphosphate (ATP).

    2. Magnesium has a direct effect on the Na+/K+-ATPase pump in both cardiac and nerve tissues. Further, magnesium has some calcium-blocking activity and may indirectly antagonize digoxin at the myocardial Na+/K+-ATPase pump.

    3. Magnesium modifies skeletal and smooth-muscle contractility. Infusions can cause vasodilation, hypotension, and bronchodilation. It can reduce or abolish seizures of toxemia.

    4. Magnesium is primarily an intracellular ion, and only 1% is in the extracellular fluid. A low serum Mg level (<1.2 mg/dL) may indicate a net body deficit of 5000 mg or more.

    5. Hypomagnesemia can be associated with a number of acute or chronic disease processes (malabsorption, pancreatitis, diabetic ketoacidosis). It may result from chronic diuretic use, cisplatin administration, or alcoholism. It is a potentially serious, life-threatening consequence of hydrofluoric acid poisoning.

  2. Indications

    1. Replacement therapy for patients with hypomagnesemia.

    2. Torsade de pointes ventricular tachycardia (See V. Ventricular dysrhythmias).

    3. Other arrhythmias suspected to be related to hypomagnesemia. Magnesium may be helpful in selected patients with cardiac glycoside toxicity but is not a substitute for digoxin-specific Fab fragments.

    4. Barium ingestions (See Barium). Magnesium sulfate can be used orally to convert soluble barium to insoluble, nonabsorbable barium sulfate if given early.

    5. Magnesium may have a role in the treatment of cardiac arrhythmias associated with aluminum and zinc phosphide intoxications.

  3. Contraindications

    1. Magnesium should be administered cautiously in patients with renal impairment to avoid the potential for serious hypermagnesemia.

    2. Heart block and bradycardia.

  4. Adverse effects

    1. Flushing, sweating, hypothermia.

    2. Depression of deep tendon reflexes, flaccid paralysis, respiratory paralysis.

    3. Depression of cardiac function, hypotension, bradycardia, general circulatory collapse (in particular with rapid administration).

    4. Gastrointestinal upset and diarrhea with oral administration.

    5. Use in pregnancy. FDA Category A. Magnesium sulfate is used commonly as an agent for premature labor (See Warfare Agents–Chemical).

  5. Drug or laboratory interactions

    1. General CNS depressants. Additive effects may occur when CNS depressants are combined with magnesium infusions.

    2. Neuromuscular blocking agents. Concomitant administration of magnesium with neuromuscular blocking agents may enhance and prolong their effect. Dose adjustment may be needed to avoid prolonged respiratory depression.

  6. Dosage and method of administration (adults and children)

    1. Magnesium can be given orally, IV, or by IM injection. When it is given parenterally, the IV route is preferred and the sulfate salt generally is used.

    2. Magnesium dosing is highly empiric and guided by both the clinical response and the estimated total body deficit of Mg based on serum levels.

    3. Adults: Give 1 g (8.12 mEq) every 6 hours IV for four doses. For severe hypomagnesemia, doses as high as 1 mEq/kg/24 h or 8–12 g/d in divided doses have been used. Magnesium sulfate can be diluted in 50–100 mL of D5W or NS and infused over 5–60 minutes. Children: Give 25–50 mg/kg ...

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.